
Results
15
Companies which are more than 50% undervalued based on analyst price target.
15 companies
Inventiva
Market Cap: €881.3m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.73
7D
9.1%
1Y
34.7%
Valneva
Market Cap: €433.7m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.18
7D
-6.8%
1Y
-13.4%
Cellectis
Market Cap: €196.2m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.59
7D
-9.2%
1Y
91.0%
Innate Pharma
Market Cap: €149.4m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.57
7D
-5.4%
1Y
4.8%
Sensorion
Market Cap: €132.8m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
0%
1Y
-16.7%
OSE Immunotherapeutics
Market Cap: €80.2m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.32
7D
-11.0%
1Y
-34.5%
Adocia
Market Cap: €76.9m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.74
7D
-16.0%
1Y
-0.5%
ABIONYX Pharma
Market Cap: €68.5m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.85
7D
-11.0%
1Y
54.3%
AB Science
Market Cap: €60.0m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.73
7D
-5.2%
1Y
-46.4%
MaaT Pharma
Market Cap: €50.9m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.78
7D
-3.5%
1Y
-40.2%
THX Pharma Société Anonyme
Market Cap: €49.3m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.74
7D
1.6%
1Y
214.3%
Nicox
Market Cap: €34.1m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.39
7D
1.0%
1Y
68.9%
Advicenne
Market Cap: €23.3m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.77
7D
26.4%
1Y
32.5%
GenSight Biologics
Market Cap: €19.4m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.082
7D
-1.0%
1Y
-34.9%
Valbiotis
Market Cap: €18.4m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.79
7D
-7.1%
1Y
-5.5%